Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) announced on April 16, 2026 that it has commenced an underwritten public offering of $150,000,000 of common stock, with a 30-day option for underwriters to purchase up to an additional $22,500,000.
The offering is subject to market conditions and will be made under its Form S-3 shelf registration; final terms will be disclosed in a prospectus supplement.
AI-generated analysis. Not financial advice.
Positive
- $150M proposed capital raise
- Underwriters granted $22.5M option (30 days)
- Offering uses existing Form S-3 shelf registration
Negative
- Potential dilution for existing shareholders from share issuance
- Completion contingent on market conditions, not guaranteed
News Market Reaction – TRVI
On the day this news was published, TRVI gained 4.75%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.1% during that session. Argus tracked a trough of -9.2% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $92M to the company's valuation, bringing the market cap to $2.02B at that time. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TRVI traded up 1.64% while closely ranked biotech peers showed mixed, mostly modest moves (e.g., DNTH +0.93%, ELVN -1.46%, LENZ -2.44%), pointing to a stock-specific setup ahead of the offering.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Offering pricing | Negative | +10.6% | Pricing of $100M underwritten common stock offering at fixed share price. |
| Jun 02 | Proposed offering | Negative | -5.8% | Announcement of proposed $100M equity raise with 30-day underwriter option. |
Prior equity offerings showed mixed reactions: one proposed deal sold off, while the subsequent pricing traded higher the next day.
Recent same-tag history shows Trevi executed a similar capital raise sequence in June 2025: a proposed $100M common stock offering followed by a priced deal the next day. The initial proposal saw a -5.78% move, but the pricing day moved up 10.59%. Today’s proposed $150M offering with an additional $22.5M option fits this pattern of funding late-stage Haduvio development via follow-on equity.
Historical Comparison
In the past, TRVI disclosed two equity offerings tagged as ‘offering,’ with an average next-day move of ±2.4%, showing that reactions to financings have varied.
Historical same-tag events show a recurring pattern of proposed offerings followed by priced underwritten deals to fund Haduvio’s development.
Market Pulse Summary
This announcement details a proposed underwritten public offering of $150,000,000 in common stock, plus a potential $22,500,000 underwriters’ option, to be issued under an existing Form S-3 registration. Historically, Trevi has used follow-on offerings to fund Haduvio’s late-stage development. Investors may watch for the final prospectus terms, the discount to the pre-announcement price, and any subsequent capital planning disclosures to assess financing impact.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of
Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares are being offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-291517), which was filed with the Securities and Exchange Commission (SEC) on November 13, 2025 and became effective automatically upon filing. This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, when filed, copies of the preliminary prospectus supplement relating to and describing the offering may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022, or by email at prospectus@cantor.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415)364-2720 or by email at syndprospectus@stifel.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the anticipated public offering and the expected size of the offering, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may,” and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as other risks and uncertainties, set forth in the “Risk Factors” section of the preliminary prospectus supplement to be filed with the SEC, in Trevi’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC and in any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.
Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
